Transmyocardial laser revascularization is a treatment for patients with severe angina pectoris not eligible for conventional revascularization. The effects on myocardial function and reversible ischaemia have not been clarified.
Introduction
Transmyocardial revascularization with laser has emerged as a surgical option in the treatment of patients with severe angina pectoris not amenable for conventional revascularization because of diffuse and distal coronary artery disease [1] [2] [3] [4] [5] [6] . The mechanisms behind the symptomatic effect are not yet revealed. There is little support of myocardial perfusion directly from the left ventricular cavity through patent laser-made channels from animal [7, 8] or autopsy studies [9] , whereas there is experimental support for angiogenesis [10, 11] and denervation effects [12, 13] after transmyocardial revascularization with laser. Convincing evidence of improved myocardial perfusion from randomized clinical studies is lacking [3] [4] [5] . Dobutamine stress echocardiography is a safe and accurate non-invasive imaging modality for detecting coronary artery disease and gives information about location and extent of reversible ischaemia [14, 15] and hibernating myocardium [16, 17] . In the present study we used serial dobutamine stress echocardiography to assess myocardial function and reversible ischaemia in patients with refractory angina pectoris, randomized to receive continued medical treatment alone or combined with transmyocardial revascularization with laser. To *Corresponding author: Overlege Lars Aaberge, Feiringklinikken, N-2093 Feiring, Norway. Phone: +47-63924400, Fax: +47-63924099. E-mail: laaaberg@online.no the best of our knowledge serial dobutamine stress echocardiography data from randomized clinical studies on patients with refractory angina pectoris receiving continued medical treatment alone or combined with transmyocardial revascularization with laser have not been published.
Methods

Design and Study Population
The study was part of The Norwegian Randomized Trial on Transmyocardial revascularization with Laser [6] , which was designed as an open, prospective, single centre study without cross-over. One hundred eligible patients were randomized 1:1 into two comparable groups to receive either continued medical treatment alone (medical treatment group) or combined with laser treatment (transmyocardial revascularization with laser group). Study tests were performed at baseline and at 3 and 12 months follow-up. Included were patients suffering angina pectoris classified as III or IV according to the New York Heart Association Functional Classification (NYHA) despite optimal medical treatment and who were not candidates for conventional revascularization because of diffuse and distal coronary artery disease. Exclusion criteria were age >75 years, left ventricular ejection fraction <30%, absence of documented viable myocardium with reversible ischaemia as assessed by exercise ECG, dobutamine stress echo and technetium 99m ( 99m Tc)-tetrofosmin myocardial perfusion scan (SPECT), overt heart failure, inability to undergo the study tests or conditions precluding thoracic surgery. Informed consent was signed by all patients prior to inclusion and the scientific protocol was approved by the Regional Ethics Committee.
Patient baseline characteristics did not differ between the treatment groups (Table 1) . Three-vessel disease with diffuse and distal changes in the arteries in all three coronary territories was present in 90% of the patients. Of these 18% had no open grafts. None of the patients was unstable with increasing symptoms during the week preceding treatment. Ninety-five per cent of the patients received beta-blocker therapy, 89% long acting nitrates and 64% calcium-channel blockers. There were no significant differences in antiangina medication between the treatment groups at baseline or during follow-up.
Surgery was performed in combined general and thoracic epidural anaesthesia without cardiopulmonary bypass. We used an 800-Watt CO2-laser (The Heart Laser; PLC Medical Systems, Inc., Milford, MA, U.S.A.). Transmyocardial revascularization with laser was performed by making channels directly through the left ventricular wall on the beating heart through a left anterior thoracotomy with pulses synchronized with R-wave in electrocardiogram (ECG). About one channel per cm 2 of presumed ischaemic and viable myocardium was made and the vascular territories to be treated were defined on the basis of dobutamine stress echocardiography and SPECT results. An average of 48 (SD 7) channels (energy range 30-50 J) were made per patient. Through a 5 MHz multiplanar ultrasound transesophageal probe (VingMed, Horten, Norway), channel formation was confirmed. Four patients suffered perioperative myocardial infarction, of whom two (4%) died. Another four patients in each treatment group died within one year of randomization. In the transmyocardial revascularization with laser group one died from cancer, one from intra-cerebral haemorrhage and two died suddenly at home, but no autopsy was performed. In the medical treatment group one died from septicaemia, one from acute myocardial infarction, one from clinical heart failure and one died suddenly. Dobutamine stress echocardiography analysis included 42 patients in the transmyocardial revascularization with laser group and 44 patients in the medical treatment group who had complete dobutamine stress echocardiography studies at baseline and at follow-ups. Only segments that were evaluated at all three investigations were included. During surgery, one patient was found to have a graftable left anterior descending coronary artery which had not been detected by coronary angiography. This patient was treated with transmyocardial revascularization with laser and a left internal mammary artery graft to the left anterior descending coronary artery, but was excluded from follow-up analysis. One patient was not able to perform the test at first and second follow-up, two patients did not meet for tests at second follow-up. Otherwise, follow-up was complete. 
Dobutamine Stress Echo
The examinations were performed with a Vingmed CFM 750 cardiac ultrasound scanner (GE Vingmed Ultrasound AS, Horten, Norway) using a duplex mechanical annular 2·5 MHz transducer. The scanner allows digital transfer of the images to a read and write optical disc (Sony EDM-1200B) for later off-line analyses, using a dedicated program for digital image handling and analysis (EchoPac, GE Vingmed Ultrasound AS, Horten, Norway). Before testing, the patients abstained from food, coffee or nicotinic consumption for 4 h and from medication for the preceding 12 h (long-acting beta-blockers were not taken during the preceding 24 h). Echocardiography was performed with the patients in the left lateral recumbent position, and the left ventricle was imaged from an apical four-chamber, two-chamber and long-axis view, and from a parasternal shortaxis and long-axis view. Cineloops comprising one heart cycle from each view were recorded at rest, during dobutamine stimulation at levels of 10 and 20 g.kg.min 1 and at maximal reached dose for each test. Discontinuation criteria were any of the following: Maximal achievable dose of 40 g.kg.min 1 dobutamine, disabling chest pain, severe new wall motion abnormalities, arrhythmia or significant side-effects from dobutamine infusion. Images were previewed on the scanner monitor before they were stored to ensure comparable views. All recordings were performed by the same investigator (LAa).
Using a 16-segment model, wall motion and thickening were analysed by visual interpretation [18] of the cineloops. Wall motion for each segment was graded as 1 (normal systolic thickening), 2 (hypokinesia), 3 (akinesia) or 4 (dyskinesia=paradox systolic movement). A bull's eye plot was produced to show the extent and localization of abnormalities, and wall motion score index (WMSI=sum of scores divided by number of scored segments) was calculated for each stress level. WMSI=1,0 indicates normal systolic thickening in all segments, and increasing score indicates impairment of left ventricular systolic function. Reversible ischaemia was defined as a reduced systolic wall thickening at stress as compared to rest in at least one segment. Hibernating myocardium was defined as areas comprising at least two contiguous segments found to have reduced systolic wall thickening at rest with improved thickening during 10 or 20 g.kg.min 1 dobutamine infusion, and a subsequent worsening at peak dose. Probably non-viable segments were segments found to have reduced systolic thickening at rest and which showed no change during dobutamine stimulation. Each examination was blinded and given a dedicated number by an independent observer. The analyses were made by one experienced observer (LAa) three months or more after blinding had been performed. Reproducibility of the technique was examined by repeated analyses of 50 randomly selected and blinded dobutamine stress echocardiography studies by the same observer (LAa) and another experienced observer (SAa). The repeated analyses were performed three months after the initial ones.
Data Analysis
WMSI and a segmental analysis were performed. For the purpose of segmental analysis, the segments were divided into three groups; normal segments were those which had normal function at rest and during stress, ischaemic segments included segments with reversible ischaemia and hibernating myocardium, while probably non-viable segments formed the third group. Each segment was given the same dedicated number at each investigation, ensuring comparisons between the same segments at all investigations and stress levels. A separate analysis was performed in a subgroup of 'clinical responders' (n=25), defined as patients who reported an improvement in symptoms to two or more angina functional classes after three or 12 months compared to baseline.
Statistics
Efficacy of transmyocardial revascularization with laser was evaluated by estimating the relative changes of the outcome variables between baseline (O BL ) and follow-up (O FU ) (RC=[O BL O FU /O BL ] 100) for each patient at three and 12 months, respectively. Results are given as mean standard deviation (SD) or frequency (%). Normal distribution was evaluated by visual distribution of the histograms of the endpoint variables and by performing the one sample Kolmogorow-Smirnov goodness of fit test, which showed approximation of the distribution to the Gaussian curve. Meanwhile, because of heterogeneity of the variance in the treatment and control group, the utilization of the parametric test was judged not to be adequate. The Mann-Whitney nonparametric test was used to compare differences between the groups at baseline and during follow-up the ChiSquare test was used to test significance level for frequency differences. Variability was defined as 2 SD of the mean difference between pairs of WMSI, and agreements between observers were assessed by Kappa-calculations. Significance was defined as P<0·05 [19] .
Results
Variability
WMSI inter-observer variability (2 SD) was 0·32 score point at rest and 0·36 score point during stress, whereas the intra-observer variability was 0·20 score point at rest as well as during stress ( Table 2 ). Except that an inter-observer difference was found in the assessment of Transmyocardial Revascularization 189 WMSI at peak stress (P<0·05), no systematic differences in assessing WMSI were found inter-and intra-observers (Fig. 1) .
Inter-observer agreement for identification of baseline wall motion abnormality was 94% (K=0·69), for identification of reversible ischaemia 92% (K=0·65) and for hibernating myocardium 64% (K=0·30). Corresponding intra-observer agreement was 92% (K=0·70), 94% (K=0·66) and 58% (K=0·13), respectively.
Baseline
At rest, left ventricular wall motion abnormalities were equally present in both groups with no significant difference in WMSI (Fig. 2, Table 3 ). Stress-induced global left ventricular wall motion abnormality, measured as the increment in WMSI from rest to peak stress, was 0·46 0·29 (34%) in the transmyocardial revascularization with laser group and 0·42 0·23 (29%) in the medical treatment group. The change from rest was highly significant (P<0·0001) with no significant difference between the groups. The segmental analysis identified normal, ischaemic and probably non-viable segments to be equally distributed in the two groups (Table 4) .
Peak heart rate, maximal dose of dobutamine and the heart rate at which chest pain was noted did not differ significantly between the groups, but fewer patients reached maximal dose of 40 g.kg.min 1 dobutamine in the transmyocardial revascularization with laser group (n=12) than in the medical treatment group (n=21) (P<0·05).
Follow-up
At rest, WMSI was 5% higher (i.e. wall motion abnormalities increased) at 3 months (P<0·01) and 12 months (P<0·05) after transmyocardial revascularization with laser compared to baseline, whereas no significant changes were noted in the medical treatment group. The difference between the groups was statistically significant (P<0·01) after 3 months, but not after 12 months (P=0·09). In the subgroup of patients who had the greatest symptomatic improvement after transmyocardial revascularization with laser (n=25), resting WMSI increased from 1·46 0·42 before to 1·61 0·52 and 1·59 0·45 at 3 and 12 months after transmyocardial revascularization with laser, respectively. The differences were statistically significant compared to baseline as well as to the medical treatment group (P<0·01) 3 and 12 months after transmyocardial revascularization with laser. However, the subgroup of responders was not statistically different from the clinical non-responders.
At peak stress, WMSI did not change significantly from baseline in any of the treatment groups or in the subgroup. Stress-induced global left ventricular wall motion abnormality was 0·38 0·24 after 3 months in the transmyocardial revascularization with laser group, which was a 17% reduction compared with baseline (P<0·01). When comparing this result with the data at rest, the difference appeared to be caused by the reduced function at rest. No significant change was seen in the medical treatment group, and no significant changes in WMSI were observed at low doses of dobutamine infusion in any of the groups.
Segmental analysis showed that the number of probably non-viable segments increased by more than 70% (P<0·01), i.e. from 52 to 93 at 3 months, and to 89 at 12 months after transmyocardial revascularization with laser. In the medical treatment group a non-significant increase from 45 to 51 at 3 months and 62 at 12 months was observed. The increase in number of probably non-viable segments was significantly higher (P<0·01) in the transmyocardial revascularization with laser group than in the medical treatment group, but no statistically significant differences were observed between the subgroups of clinical responders and nonresponders. The number of normal segments did not change significantly in any of the groups. Compared with the medical treatment group a statistically significant (P<0·05) reduction was observed in the number of ischaemic segments by 14% at 3 months and 9% 12 months after transmyocardial revascularization with laser, whereas no significant changes occurred in the medical treatment group.
After transmyocardial revascularization with laser, the number of patients who had the dobutamine infusion discontinued due to chest pain fell by 30% and a higher number of patients (n=18 after three and n=23 after 12 months) tolerated maximum dose of dobutamine, whereas no significant changes were observed in the medical treatment group (Table 5 ). The differences were statistically significant (P<0·01) within the transmyocardial revascularization with laser group compared with both baseline and the medical treatment group. However, heart rate at onset of chest pain, Transmyocardial Revascularization 191 maximal dose of dobutamine and maximal heart rate did not change significantly. The subgroup of 25 patients with the greatest symptomatic improvement was not statistically different from the complete transmyocardial revascularization with laser group or medical treatment group in this respect. Generally, no significant changes were observed in the medical treatment group after 3 and 12 months.
Discussion
The present study has demonstrated a slightly reduced resting global systolic left ventricular function after transmyocardial revascularization with laser, whereas the function during stress was preserved. There was a trend towards a greater reduction in resting left ventricular systolic function in the subgroup of clinical responders (n=25), but the difference was not statistically significant as compared to the clinical non-responders. After transmyocardial revascularization with laser, the number of probably non-viable segments increased with a subsequent decrease in the number of ischaemic segments, whereas the number of normal segments remained unchanged. In addition, fewer patients had the dobutamine infusion discontinued because of chest pain after transmyocardial revascularization with laser.
The higher WMSI at rest and the preserved WMSI during stress may be explained by a change of ischaemic segments with severe wall motion abnormalities during stress into non-viable segments. This also complies with the reduction in stress-induced wall motion abnormality after transmyocardial revascularization with laser. The consistency in the results from the medical treatment group is important, and the lack of significant changes in WMSI or in the number of ischaemic and probably non-viable segments in the medical treatment group indicates that left ventricular function was well preserved in these patients during the 12-month follow-up. We have not found other published randomized studies assessing myocardial function by dobutamine stress echocardiography after transmyocardial revascularization with laser with which to make comparisons. However, Donovan et al. [20] reported from a nonrandomized echocardiographic study, an improvement in wall motion abnormality at peak stress 3 months after transmyocardial revascularization with laser, but with no change at rest. Our findings are supported by a significant reduction in resting left ventricular ejection fraction after transmyocardial revascularization with laser, as reported by Burkhoff et al. [3] , whereas the changes reported by Schofield et al. [5] were not statistically significant. A slight, but statistically insignificant reduction in left ventricular ejection fraction determined by multiple-gated acquisition (MUGA) after transmyocardial revascularization with laser was also reported in the Norwegian trial [6] . Left ventricular ejection fraction determined by MUGA and WMSI represent two different ways of measuring left ventricular systolic function. The changes in WMSI were small, and the study may not have been powered to show significant changes determined by MUGA. With a type 1 error of 5% the power to show between-group difference in WMSI after 3 months in the present study was more than 80%, while due to considerable variability in the outcome variable the study was underpowered (46%) to show significance between the groups after 12 months.
A symptomatic effect and an increase in the chest pain threshold after transmyocardial revascularization with laser have been reported from clinical studies [3] [4] [5] 21, 22] . Even if fewer patients had the dobutamine infusion discontinued due to chest pain after transmyocardial revascularization with laser, chest pain threshold did not increase significantly in the present study. A lower number of patients tolerated maximal dobutamine dose at baseline in the transmyocardial revascularization with laser group than in the medical treatment group. This could be incidental and may explain why a reduced number of patients had the dobutamine infusion discontinued after transmyocardial revascularization with laser, whereas their pain threshold was unchanged. However, it may also support a symptomatic effect of transmyocardial revascularization with laser.
Denervation may partly explain the immediate relief of symptoms after transmyocardial revascularization with laser [12, 13] . Improved regional myocardial perfusion should reduce stress induced myocardial ischaemia and improve left ventricular function during stress [14] . Furthermore, if hibernating myocardium was present preoperatively, an improved resting left ventricular systolic function was to be expected [16] . Improved left ventricular function was, however, not observed at rest or during stress. Some of the symptomatic effects seen after transmyocardial revascularization with laser could be caused by a process where ischaemic myocardium progressed into non-viable myocardium (or fibrosis), with a subsequent reduction in the amount of myocardium getting ischaemic during stress. We did not observe statistical differences between the responders and non-responders regarding the change in WMSI or in the number of ischaemic segments. However, the study was underpowered to demonstrate such differences. Perhaps destruction of ischaemic tissue is not the mechanism, but rather a cost for a symptomatic effect. Our study does not answer the question of possible placebo effects after transmyocardial revascularization with laser.
The quality of dobutamine stress echocardiography is dependent on investigator experience, image reading technique and quality of ultrasound images [23] . Our inter-and intra-observer study on the study population showed a low intra-observer variability, whereas interobserver variation increased at peak stress. The presented results are therefore based on the dobutamine stress echocardiography readings of one observer (LAa). Inter-and intra-observer agreements were high for baseline wall motion abnormalities and reversible ischaemia, but somewhat lower for hibernating myocardium. As in addition few segments were characterized as hibernating, we decided not to present data on isolated hibernating myocardium and included those into the group of ischaemic segments. Consequently, the study does not answer the question of whether more hibernating segments or more segments with reversible ischaemia were damaged following transmyocardial revascularization with laser.
Clinical and experimental studies have shown that angiogenesis can be observed within 2 weeks following transmyocardial revascularization with laser [9] [10] [11] . The laser energy and the natural healing processes may, TMR=transmyocardial revascularization; MT=medical treatment; non-viable segments=segments with reduced systolic thickeningat rest and with no change during stress; ischaemic segments=segments with reduced systolic thickening at peak stress compared to rest+damaged segments with improved thickening at stress; normal segments=segments with normal systolic thickening at rest and during stress; P*=significance between groups during follow-up. however, cause complications and tissue damage [24] [25] [26] [27] . An average of 48 channels and a pulse duration of 30-50 ms were used in the present study, and this potentially may cause myocardial damage with subsequent impaired myocardial function. The reduced myocardial function after transmyocardial revascularization with laser was only seen at rest and affected only ischaemic myocardium. This indicates that mainly ischaemic myocardium was treated with laser. However, if normal myocardium was also to some extent treated, the results indicate that normal myocardium is more resistant to damage caused by the treatment. Two patients suffered postoperative myocardial infarction. However, the infarcts affected only a few myocardial segments. The overall results were not altered when we excluded these patients from the analysis.
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Conclusions
In the present study, myocardial function in patients with refractory angina was assessed by serial dobutamine stress echocardiography, following continued medical treatment alone or in combination with transmyocardial revascularization with laser. The study gives support for reduced stress-induced myocardial ischaemia after transmyocardial revascularization with laser, and that this is caused by progression of some ischaemic myocardium into non-viable myocardium or fibrosis. No significant changes were observed following 12 months' medical treatment alone. The observed symptomatic effect after transmyocardial revascularization with laser, however, could not be explained by the destruction of ischaemic myocardium. The mechanisms behind the symptomatic effects of transmyocardial revascularization with laser are still unknown and require further elucidation.
